Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, a developer of antibody-based cancer therapies, filed new patent applications during the first half of 2026. They cover its BiTAC-TCE (T-cell engager) and BiTAC-ADC (antibody-drug conjugate) technology platforms and related therapeutic programs.

Key details

  • Previously granted patents protecting supporting technologies have cleared the opposition period, the window in which others can challenge a granted patent.
  • The portfolio now stands at more than 50 granted patents, owned or exclusively licensed, across 14 countries and 26 patent families.
  • VERAXA says its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present.
  • VERAXA also cited its own click chemistry, conjugation, linker and payload technologies, which it says are intended to improve the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines.

What’s still pending

  • The new patent applications are pending approval.
  • If the latest filings are approved, VERAXA expects its core technologies to be protected through at least 2047.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, July 29th, 2026, NewsDirect

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.

The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.

To view the full press release, visit https://ibn.fm/BqhFS

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.com[email protected]

Veraxa Biotech AG on 6ix

Story so far

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases